Skip to main content

Developing innovative medicines
to improve the lives of
patients and their families

At BIORCHESTRA, we develop transformational RNA medicines and delivery systems that will solve major unmet medical needs in neurodegenerative and rare diseases of the Central Nervous System.


From Novel Target Discovery to First-in-Class Drug Development

Our Discovery

Our Target

Our Approach

Join our pioneering team

Join our pioneering team of world-class researchers and passionate colleagues, fighting for the health and well-being of all, including those closest to our hearts.


News & Press releases


IR Event

Polymer Chemistry&Formulation in Drung Delivery Summit, May 21-23 2024 I Boston, MA

February 21, 2024
Please join us for an enlightening session on Brain Target Delivery of RNA Therapeutics using…
IR Event

RNA Leaders Europe Congress, March 13-14 2024 I Basel, Switzerland

February 21, 2024
BIORCHESTRA is excited to announce that David Oxley, our Chief Business Officer (CBO), will be…
Press Release

BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program

July 17, 2023
Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS Underpinned by proprietary…

The microRNA-485-3p concentration in salivary exosome-enriched extracellular vesicles is related to amyloid β deposition in the brain of patients with Alzheimer’s disease

July 13, 2023
Objectives Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by progressive long-term memory loss…


Stay Connected